Discovery Research, Lantheus Medical Imaging, 331 Treble Cove Rd, N Billerica, MA 01826, USA.
Nucl Med Biol. 2013 Jul;40(5):682-8. doi: 10.1016/j.nucmedbio.2013.03.003. Epub 2013 Apr 17.
Released sympathetic neurotransmitter norepinephrine (NE) in the heart is cleared by neuronal uptake-1 and extraneuronal uptake-2 transporters. Cardiac uptake-1 and -2 expression varies among species, but the uptake-1 is the primary transporter in humans. LMI1195 is an NE analog labeled with (18)F for PET evaluation of cardiac neuronal function. This study investigated the impact of cardiac neuronal uptake-1 associated with different species on LMI1195 heart uptake.
Cardiac uptake-1 was blocked by desipramine, a selective uptake-1 inhibitor, and sympathetic neuronal denervation was induced by 6-hydroxydopamine, a neurotoxin, in rats, rabbits and nonhuman primates (NHP). Tissue biodistribution and cardiac imaging of LMI1195 and (123)I-metaiodobenzylguanidine (MIBG) were performed.
In rats, uptake-1 blockade did not alter LMI1195 heart uptake compared to the control at 60-min post injection [1.41 ± 0.07 vs. 1.47 ± 0.23 % injected dose per gram tissue (%ID/g)]. In contrast, LMI1195 heart uptake was reduced by 80% in uptake-1 blocked rabbits. In sympathetically denervated rats, LMI1195 heart uptake was similar to the control (2.18 ± 0.40 vs. 2.58 ± 0.76 %ID/g). However, the uptake decreased by 79% in denervated rabbits. Similar results were found in MIBG heart uptake in rats and rabbits with uptake-1 blockade. Consistently, LMI1195 cardiac imaging showed comparable myocardial activity in uptake-1 blocked or sympathetically denervated rats to the control, but marked activity reduction in uptake-1 blocked or denervated rabbits and NHPs.
LMI1195 is retained in the heart of rabbits and NHPs primarily via the neuronal uptake-1 with high selectivity and can be used for evaluation of cardiac sympathetic denervation. Similar to the human, the neuronal uptake-1 is the dominant transporter for cardiac retention of NE analogs in rabbits and NHPs, but not in rats.
在心脏中释放的去甲肾上腺素(NE)通过神经元摄取-1 和非神经元摄取-2 转运体清除。心脏摄取-1 和 -2 的表达在不同物种之间存在差异,但摄取-1 是人类的主要转运体。LMI1195 是一种用 (18)F 标记的 NE 类似物,用于 PET 评估心脏神经元功能。本研究探讨了与不同物种相关的心脏神经元摄取-1 对 LMI1195 心脏摄取的影响。
用选择性摄取-1 抑制剂去甲丙咪嗪阻断心脏摄取-1,用神经毒素 6-羟多巴胺诱导大鼠、兔和非人灵长类动物(NHP)的交感神经去神经支配。进行 LMI1195 和 (123)I-间碘苄胍(MIBG)的组织分布和心脏成像。
在大鼠中,与对照组相比,60 分钟时摄取-1 阻断并未改变 LMI1195 心脏摄取[1.41 ± 0.07% 与 1.47 ± 0.23% 注射剂量/克组织(%ID/g)]。相比之下,LMI1195 心脏摄取在摄取-1 阻断的兔子中减少了 80%。在去交感神经支配的大鼠中,LMI1195 心脏摄取与对照组相似[2.18 ± 0.40% 与 2.58 ± 0.76%ID/g]。然而,在去神经支配的兔子中,摄取量减少了 79%。在大鼠和兔子中,MIBG 心脏摄取也有类似的结果,即摄取-1 阻断或去交感神经支配时,摄取量减少。一致地,LMI1195 心脏成像显示,与对照组相比,摄取-1 阻断或去交感神经支配的大鼠心肌活性相当,但在摄取-1 阻断或去神经支配的兔子和 NHP 中活性明显降低。
LMI1195 主要通过神经元摄取-1 在心脏中保留,具有高选择性,可用于评估心脏交感神经去神经支配。与人类相似,神经元摄取-1 是兔子和 NHP 中 NE 类似物在心脏中保留的主要转运体,但不是在大鼠中。